Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13
Clinical Immunology · 2025-06 · 275 · 110476
DOI: 10.1016/j.clim.2025.110476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2025-06. Verfasst von Nora Euler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Center for Molecular Medicine, Stoc…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Lymphoma, Large B-Cell, Diffuse, Chemokine CXCL13, B-Lymphocytes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Rheumatism Association, Region Uppsala, Swedish Cancer Society.
Abstract (Originalsprache)
Patients with rheumatoid arthritis (RA) are at increased risk of diffuse large B cell lymphoma (DLBCL) compared to the general population. Here, we explored the inflammatory profiles in the blood of RA patients who had developed DLBCL. RA-DLBCL patients had significantly higher levels of the pro-inflammatory markers TNF, IL-8, CXCL9, APRIL, and particularly CXCL13 (median 796 vs. 206 pg/mL, p = 0.001), compared to RA controls. By including an extensive autoantibody panel of rheumatoid factor, IgG anti-CCP2, anti-citrullinated protein antibodies (ACPA) fine-specificities, and other anti-modified protein antibodies, all RA-DLBCL patients were autoantibody seropositive. Yet, RA-DLBCL patients did not display significantly different autoantibody signatures compared to RA controls. The levels of immunoglobulin free light chains and C-reactive protein were similar in RA-DLBCL patients and RA controls. In conclusion, RA-DLBCL patients exhibit pro-inflammatory signatures with elevated markers that are important for B cells and may contribute to enhanced B-cell activation and promote lymphoma development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
- Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
- Department of Immunology, Genetics and Pathology: Cancer Immunotherapy, Uppsala University, Uppsala, Sweden.
- Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden. Electronic address: caroline.gronwall@ki.se.
Förderung
- Swedish Rheumatism Association
- Region Uppsala
- Swedish Cancer Society
- Landstinget i Uppsala län
- Swedish Research Council
- Agnes and Mac Rudberg foundation
Zitieren
APA
Euler, N., Hellbacher, E., Klint, E. A., Hansson, M., Larsson, A., Enblad, G., Malmström, V., Baecklund, E., Grönwall, C., & AUTO-LYMPHOMA study group (2025). Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13. Clinical Immunology, 275, 110476. https://doi.org/10.1016/j.clim.2025.110476
Vancouver
Euler N, Hellbacher E, Klint EA, Hansson M, Larsson A, Enblad G, et al. Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13. Clinical Immunology. 2025;275:110476. doi:10.1016/j.clim.2025.110476
BibTeX
@article{Euler2025,
author = {Euler, Nora and Hellbacher, Erik and Klint, Erik Af and Hansson, Monika and Larsson, Anders and Enblad, Gunilla and Malmström, Vivianne and Baecklund, Eva and Grönwall, Caroline and AUTO-LYMPHOMA study group, AUTO-LYMPHOMA study group},
title = {Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13},
journal = {Clinical Immunology},
year = {2025},
volume = {275},
pages = {110476},
doi = {10.1016/j.clim.2025.110476}
}
EUVIMED